echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Subcutaneous RNAi therapy ALN-AGT Phase 1 clinical trial results are positive

    Subcutaneous RNAi therapy ALN-AGT Phase 1 clinical trial results are positive

    • Last Update: 2021-04-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    About 1.


    ALN-AGT is an RNAi therapy targeting mRNA that expresses angiotensinogen.


    In this randomized, double-blind, placebo-controlled clinical trial, a total of 84 hypertensive patients received different doses of ALN-AGT.


    Moreover, as the AGT level drops, the patient's blood pressure also drops at the same time.


    Note: The original text has been deleted

    Reference materials:

    [1] Alnylam Presents Positive Late-Breaking Data from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension.


    [2] Safety, Pharmacodynamics, and Blood Pressure Effects of ALN-AGT, an RNA Interference Therapeutic Targeting Angiotensinogen, in a Randomized Single Ascending Dose Study of Hypertensive Adults.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.